CERT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

103.41M

+3.04%

0.102

-31.98%

110.64M

+4.37%

0.142

+1.09%

110.61M

+5.78%

0.135

+92.26%

Estimates Revision

The market is revising Downward the revenue expectations for Certara, Inc. (CERT) for FY2025, with the revenue forecasts being adjusted by -0.8% over the past three months. During the same period, the stock price has changed by -21.33%.

Revenue Estimates for FY2025

Revise Downward

-0.8%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.32%

In Past 3 Month

Stock Price

Go Down

-21.33%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast CERT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERT is 13.71 USD with a low forecast of 9.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.00

Averages

13.71

High

16.00

Current: 0.000

Low

9.00

Averages

13.71

High

16.00

KeyBanc

Overweight

downgrade

$13 -> $12

2026-01-08

New

Reason

KeyBanc

Price Target

$13 -> $12

2026-01-08

New

downgrade

Overweight

Reason

KeyBanc lowered the firm's price target on Certara to $12 from $13 and keeps an Overweight rating on the shares. Coming off a choppy year for HCIT stocks, fundamentally, the firm did see a "year of inflection" for many of its names with estimate revisions plus valuations largely bottoming. While KeyBanc expects momentum to continue for most of its coverage, the firm does see valuation multiples impacted by competition concerns and regulatory impacts.

Leerink

Market Perform -> Outperform

upgrade

$13

2026-01-06

New

Reason

Leerink

Price Target

$13

2026-01-06

New

upgrade

Market Perform -> Outperform

Reason

Leerink upgraded Certara to Outperform from Market Perform with an unchanged price target of $13. The firm says the company remains a leader in the "broad-based" biosimulation market. It attributes the stock's underperformance in late 2025 to softer Q3 services bookings, market uncertainty tied to biopharma budget delays, and the recently announced CEO change. The selloff "overplays" Certara's "durable growth engine," the analyst tells investors in a research note. Leerink believes the improving market backdrop should drive Certara shares higher.

Morgan Stanley

Equal Weight

downgrade

$16 -> $12

2025-12-18

Reason

Morgan Stanley

Price Target

$16 -> $12

2025-12-18

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Certara to $12 from $16 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an "attractive backdrop for alpha-generation opportunities" in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing "another year of unprecedented policy, reimbursement, and utilization headwinds," the analyst added in a year-ahead outlook note for the Healthcare Services group.

Barclays

Luke Sergott

Overweight

maintain

$14 -> $13

2025-12-15

Reason

Barclays

Luke Sergott

Price Target

$14 -> $13

2025-12-15

maintain

Overweight

Reason

Barclays analyst Luke Sergott lowered the firm's price target on Certara to $13 from $14 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Stephens

Overweight

maintain

$15 -> $12

2025-12-12

Reason

Stephens

Price Target

$15 -> $12

2025-12-12

maintain

Overweight

Reason

Stephens lowered the firm's price target on Certara to $12 from $15 and keeps an Overweight rating on the shares after the company appointed Jon Resnick as CEO and member of the board, succeeding William Feehery, and reaffirmed its FY25 outlook with the announcement. The firm, which believes this leadership change should be viewed as a potential catalyst on commercial execution, "rather than a precursor of deeper change or strategy shift," cites its post-Q3 model updates for its revised price target.

Rothschild & Co Redburn

Buy

initiated

$10

2025-11-21

Reason

Rothschild & Co Redburn

Price Target

$10

2025-11-21

initiated

Buy

Reason

Rothschild & Co Redburn initiated coverage of Certara with a Buy rating and $10 price target. The firm views Certara as the leader in biosimulation, which it says can aid the discovery of potential drug targets and reduce the need for early stage clinical work. Certara needs to increase penetration into discovery and preclinical phases, and it acquisition of Chemaxon boosts its presence in these areas, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Certara Inc (CERT.O) is 16.96, compared to its 5-year average forward P/E of 47.22. For a more detailed relative valuation and DCF analysis to assess Certara Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

47.22

Current PE

16.96

Overvalued PE

78.89

Undervalued PE

15.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

24.89

Current EV/EBITDA

11.03

Overvalued EV/EBITDA

35.99

Undervalued EV/EBITDA

13.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.42

Current PS

3.20

Overvalued PS

12.64

Undervalued PS

4.20

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CERT News & Events

Events Timeline

No data

News

4.0

01-06Yahoo Finance

Certara (CERT) Shares Rise 4.4% Following Leerink Partners Upgrade

6.5

01-05Fool

Kopion Asset Management Buys 327,064 Shares of Certara for $3.37 Million

6.5

01-05NASDAQ.COM

Kopion Asset Management Acquires 327,064 Certara Shares for $3.37 Million

People Also Watch

Frequently Asked Questions

What is Certara Inc (CERT) stock price today?

The current price of CERT is 9.33 USD — it has decreased -3.52 % in the last trading day.

What is Certara Inc (CERT)'s business?

Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

What is the price predicton of CERT Stock?

What is Certara Inc (CERT)'s revenue for the last quarter?

Certara Inc revenue for the last quarter amounts to 104.62M USD, increased 10.33 % YoY.

What is Certara Inc (CERT)'s earnings per share (EPS) for the last quarter?

Certara Inc. EPS for the last quarter amounts to 0.01 USD, decreased -200.00 % YoY.

What changes have occurred in the market's expectations for Certara Inc (CERT)'s fundamentals?

How many employees does Certara Inc (CERT). have?

Certara Inc (CERT) has 1487 emplpoyees as of January 10 2026.

What is Certara Inc (CERT) market cap?

Today CERT has the market capitalization of 1.49B USD.